Goldman Sachs analyst Davin Thillainathan initiated coverage of Sonic Healthcare (SKHHY) with a Buy rating and A$32.20 price target While funding reforms in Germany are a headwind to the company’s growth, they are unlikely to come as a surprise to investors given the industry’s track record of withstanding cuts to reimbursement, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKHHY: